Association of serum fetuin-A levels with mortality in dialysis patients  by Hermans, M.M.H. et al.
see commentary on page 137
Association of serum fetuin-A levels with mortality
in dialysis patients
MMH Hermans1,6, V Brandenburg2,6, M Ketteler2, JP Kooman1, FM van der Sande1, EW Boeschoten3,
KML Leunissen1, RT Krediet4 and FW Dekker5, for The Netherlands cooperative study on the adequacy
of Dialysis (NECOSAD)
1Department of Internal Medicine and Nephrology, Academic Hospital Maastricht, Maastricht, The Netherlands; 2Department
of Nephrology and Clinical Immunology, University Hospital Aachen, RWTH, Germany; 3Hans Mak Institute, Naarden, The Netherlands;
4Department of Nephrology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands and 5Department
of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
Calcifying atherosclerosis is an active process, which is
controlled by calcification inhibitors and inducers. Fetuin-A,
an acute phase glycoprotein, is one of the more powerful
circulating inhibitors of hydroxyapatite formation.
A prospective multicenter cohort study was initiated to
include both hemodialysis (HD) and peritoneal dialysis (PD)
patients in an evaluation of the association of serum fetuin-A
levels with both cardiovascular (CV) and non-CV mortality.
An increase in the serum fetuin-A concentration of 0.1 g/l
was associated with a significant reduction in all-cause
mortality of 13%. There was a significant 17% reduction
in non-CV mortality and a near significant reduction in
CV mortality. This association of fetuin-A and mortality rates
was comparable in both HD and PD patients even when
corrected for factors, including but not limited to age,
gender, primary kidney disease, C-reactive protein levels,
and nutritional status. We conclude that serum fetuin-A
concentrations may be a general predictor of mortality
in dialysis patients.
Kidney International (2007) 72, 202–207; doi:10.1038/sj.ki.5002178;
published online 7 March 2007
KEYWORDS: calcification inhibitor; mortality; dialysis; cohort study
Cardiovascular (CV) mortality in patients with end-stage
renal disease is markedly increased and substantially related
to accelerated calcifying atherosclerosis.1–4 In this context,
derangements of calcium-phosphate metabolism seem to
play an important role.5,6 Disturbances of the calcium-
phosphate metabolism are also associated with a greater
mortality in both peritoneal (PD) and hemodialysis (HD)
patients.7,8
Recently, it has been shown that the calcification process
as seen in calcifying atherosclerosis is an active, cellular
process, which is controlled by calcification inhibitors and
inducers.9,10 Fetuin-A, a glycoprotein with a molecular
weight of about 60 kDa, is synthesized by hepatocytes and,
based on current knowledge, represents the most powerful
circulating calcification inhibitor of hydroxyapatite forma-
tion. Fetuin-A reacts as a negative acute phase protein, thus
downregulation may occur in acute and chronic inflamma-
tory states.11,12 In end-stage renal disease patients serum
fetuin-A concentrations were associated with increased
coronary arterial and valvular calcification scores.13,14
Until now four studies have been published on the
relationship between serum fetuin-A concentrations with
all-cause and CV mortality in dialysis patients.14–17 All
studies showed that a lower serum fetuin-A concentration
was associated with increased mortality. There is, however,
still controversy whether fetuin-A deficiency should be
regarded as an inflammation-dependent or independent risk
predictor, as results vary in this context.
Another point of discussion is whether fetuin-A is
primarily related to CV or non-CV mortality. Whereas in
the study by Ketteler et al.15 the association between fetuin-A
concentrations and CV mortality was less pronounced
compared with all-cause mortality, Stenvinkel et al.,16 showed
that fetuin-A was even a stronger predictor of CV mortality
than C reactive protein (CRP). Moreover, there is no study in
a larger cohort enabling comparisons between HD and PD
patients on this issue.14 This differentiation might be
of importance, as we observed significantly higher fetuin-A
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levels in PD patients compared with HD patients in a recently
published smaller study cohort.18
The aim of the present large, prospective, observational,
cohort study was to evaluate the association of serum fetuin-
A with mortality in Dutch incident HD and PD patients. Our
primary hypothesis was that fetuin-A was not only related to
CV, but also to non-CV mortality. The second hypothesis was
that fetuin-A was equally associated with mortality in HD
and PD patients. Our last hypothesis was that inflammation
influenced the association between fetuin-A and mortality.
RESULTS
Between January 1997 and October 2004 serum samples were
available for fetuin-A measurements in 996 patients. Eight
patients were excluded from the analysis because of missing
data concerning survival and dialysis modality. Of the
remaining 987 patients, 664 (67%) were on HD and 323
(33%) on PD. Of the 323 PD patients, 136 (42%) underwent
a kidney transplantation compared with 154 (23%) of the
HD patients. Censoring due to regaining of renal function,
refusal of further participation in the study or changing to
a non-The Netherlands Cooperative Study on the Adequacy
of Dialysis related dialysis center was observed in 91 HD
(14%) patients and 37 (11%) PD patients. Of the 987
patients included in the final analysis, 93% were Caucasian,
5% Asian, and 2% were of African or Carribean origin.
Baseline characteristics of the patients are shown in Table 1.
Compared with PD patients, HD patients were older (63 vs
53 years; Po0.001), had more cardiovascular disease (CVD)
(40 vs 27%; Po0.001) and a lower residual renal function
(3.5 vs 4.3 ml/min; Po0.001).
Relation between fetuin-A and other relevant parameters
Serum fetuin-A negatively correlated with high sensitive CRP
(hsCRP) (R¼0.27; Po0.01) and age (R¼0.26; Po0.01)
and positively correlated with serum albumin (R¼ 0.18;
Po0.01) and serum Ca levels, which were corrected for
serum albumin before analysis (R¼ 0.13; Po0.01). After
adjustment for age, dialysis modality, hsCRP, Ca, albumin,
and diabetes mellitus, women had higher serum-fetuin-A
levels compared with men (0.67 vs 0.62 g/l; Po0.01).
Survival analyses
Overall, during follow-up time of 987 subjects, 396 died, 93 of
323 PD patients (29%) and 303 of 664 HD patients (46%).
Kaplan–Meier survival curves show the associations between
serum fetuin-A concentrations divided in tertiles with
respect to low (0.25–0.55 g/l), median (0.56–0.69 g/l) and high
values (0.70–1.53 g/l) for all-cause (n¼ 396) (Figure 1) and CV
(n¼ 187) (Figure 2a) and non-CV mortality (n¼ 209) (Figure
2b). Maximal follow-up time was 8.5 years (1997–2005) and
median follow-up time was 2.8 years. A decrease from high to
low levels in serum fetuin-A concentration was associated with
a significant increase in CV (log-rank 13.0; Po0.001) and
non-CV mortality (log-rank 21.2; Po0.001).
First, a Cox-regression analysis was performed to calculate
the adjusted hazard ratios (HR) for overall, CV and non-CV
death in the total dialysis population (HD and PD patients).
Table 2 shows the crude and adjusted HRs of an increase of
0.1 g/l fetuin-A for the different models. After adjustment for
age, sex, diabetes mellitus, primary kidney disease, CVD,
dialysis modality, and current smoking, an increase in serum
fetuin-A of 0.1 g/l was associated with an HR of 0.87 (95%
confidence interval (CI) 0.80–0.93; Po0.001) for all-cause
mortality, an HR of 0.90 (95% CI 0.81–1.00; P¼ 0.09) for CV
mortality, and an HR of 0.83 (95% CI 0.75–0.92; P¼ 0.001)
for non-CV mortality. Further adjustment with addition of
the inflammation parameter log-hsCRP and addition of
parameters of nutritional state, albumin, body mass index,
and subjective global assessment (SGA) (model 3) resulted in
Table 1 | Baseline characterisics
All (n=987) HD (n=664) PD (n=323) P-value; HD vs PD
Age (years) 60714 63714 53714 o0.001
Sex (% men) 59 57 64 0.028
Primary kidney disease (%)
Diabetes 15 16 15 NS
Glomerulonephritis 13 11 19 o0.001
Renal vascular disease 19 21 13 0.002
Diabetes (%) 22 24 20 NS
Cardiovascular disease (%) 35 40 27 o0.001
Current smoking (%) 23 21 25 NS
Residual GFR 3.872.8 3.572.7 4.372.8 o0.001
SGA (% malnourished) 27 32 19 o0.001
Body mass index (kg/m2) 24.874.2 24.774.4 24.973.8 NS
hsCRP (g/l)a 4.9 (0.1–375) 5.8 (0.1–375.0) 3.1 (0.1–160.0) o0.001
Albumin (g/l) 3670.7 3570.7 3670.5 0.02
Fetuin-A (g/l) 0.6470.17 0.6070.15 0.7270.17 o0.001
Calcium (mmol/l) 2.3670.28 2.3170.39 2.4370.30 o0.001
Phosphorus (mmol/l) 1.8370.58 1.8870.63 1.7170.51 o0.001
GFR, glomerular filtration rate/ml/min/1.73 m2; HD, hemodialysis; hsCRP, high sensitivity C-reactive protein; PD, peritoneal dialysis; SGA, subjective global assessment.
Al continuous data expressed as mean7s.d.
aMedian and range.
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a small increase in the HRs for all categories of mortality.
Further adjustments for Ca and phosphate (PO) did not
materially change the results (model 4).
No significant difference was observed in the association
of fetuin-A with mortality between the lowest and highest
hsCRP tertiles (data not shown). We tested formal inter-
action between fetuin-A and CRP on the association between
fetuin-A and CV and non-CV mortality. No significant
interaction was observed (P¼ 0.25 and 0.19, respectively).
Additional analysis
Additional adjustment for residual renal function and Khan
comorbidity score did not materially alter the results.
Comparison between PD and HD patients
Compared with PD patients, HD patients had a lower
fetuin-A concentration (0.60. vs 0.72 g/l; Po0.001) and a
higher hsCRP (5.8 vs 3.1 g/l; P¼ 0.002). The difference in
fetuin-A concentration persisted after adjustment for poten-
tial confounders, including age, sex, diabetes, residual renal
function, the presence of CVD, hsCRP, Ca, P, and albumin
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Figure 1 | Kaplan-Meier curve showing all-cause mortality, by
tertile of serum fetuin-A concentration (low (0.25–0.55 g/l),
median (0.56–0.69 g/l), and high (0.70–1.53 g/l)) in all dialysis
patients.
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Figure 2 | (a and b) Kaplan–Meier curve showing CV mortality (a) and non-CV mortality (b), by tertile of serum fetuin-A
concentration (low (0.25–0.55 g/l), median (0.56–0.69 g/l), and high (0.70–1.53 g/l)) in all dialysis patients.
Table 2 | Cox-regression showing association of serum fetuin-A concentration with overall, CV and non-CV mortality
(expressed per 0.1 g/l increase in fetuin-A, hazard ratio with 95% CI) in all patients (n=987)
Overall mortality (n=396) CV-mortality (n=187) Non-CV mortality (n=209)
Model HR 95% CI HR 95% CI HR 95% CI
Fetuin-A 1 0.80 0.75–0.86 0.83 0.75–0.91 0.76 0.69–0.84
2 0.87 0.80–0.93 0.90 0.81–1.00 0.83 0.75–0.92
3 0.91 0.84–0.98 0.91 0.80–1.02 0.90 0.80–1.00
4 0.91 0.84–0.99 0.92 0.82–1.05 0.89 0.79–1.00
BMI, body mass index; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; hsCRP, high sensitivity C-reactive protein.
Model 1, crude.
Model 2, model adjusted for age, sex, diabetes mellitus, primary kidney disease, cardiovascular disease, dialysis modality, and current smoking.
Model 3, model 2 + adjustments for, log-hsCRP, albumin, subjective global assessment, and BMI.
Model 4, model 3 + adjustments for calcium and phosphate.
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(Figure 3). Forty-two percent of the HD patients had fetuin-
A levels below 0.55 g/l, compared with 15% of the PD
patients. Nonetheless, no significant difference was observed
in the association of fetuin-A with CV or non-CV mortality
between the two dialysis modalities (dialysis modality
interaction analysis, P¼ 0.07).
Fetuin-A and hsCRP levels in CVD patients
Compared with patients without CVD, fetuin-A levels in
patients with CVD were not different after adjustment for
age, sex, hsCRP, and the presence of diabetes mellitus. After
correction for age, sex, and the presence of diabetes mellitus,
dialysis patients with prevalent CVD had increased hsCRP
levels.
DISCUSSION
The general strength of this study was the large and well-
defined Dutch cohort of incident dialysis patients (n¼ 987)
and the ability to study the impact of fetuin-A on different
types of mortality, simultaneously both in HD and PD
patients. Three main findings were observed. First, a lower
serum fetuin-A concentration, 3 months after the initiation
of dialysis treatment, is independently associated with an
increased all-cause mortality. Second, survival benefits of a
higher serum fetuin-A concentration are seen both with CV
and non-CV survival, although both these relationships
weakened after adjustment for confounders. Third, the found
associations did not differ significantly between HD and PD
patients, respectively.
Until now, serum fetuin-A was found to be associated with
all-cause and CV mortality in dialysis patients, in four
smaller studies with a total of 875 patients.14–17 None of
these studies had separately analyzed non-CV mortality.
Wang et al.14 and Ketteler et al.15 showed that the association
of fetuin-A to all-cause mortality was stronger than to CV
mortality and that the association disappeared after adding
inflammation to the regression model. This was in contrast to
the findings of Stenvinkel et al.16 who found that fetuin-A
was even stronger related to CV mortality than CRP.
Our data extend the previously published studies in terms
of cohort size as well as follow-up time and show that serum
fetuin-A deficiency is a predictor of both non-CV and CV
mortality. Moreover, fetuin-A predicted all-cause mortality
even after various adjustments.
This finding is of interest, as it was always suspected
that the major link between low fetuin-A levels and mortality
was caused by accelerated CV calcification with consecutively
increased CV mortality.13,14 This view is supported by data
showing that the burden of arterial calcifications in dialysis
patients is associated with CV and all-cause mortality.3
However, fetuin-A exerts multiple physiological effects
beyond extraosseous calcification inhibition (e.g. transform-
ing growth factor-b antagonism, modification of insulin-
receptor-mediated growth effects).19 Subgroup analysis in the
presented cohort showed that 22% of the non-CV death was
caused by infection. However, in a multiple regression model
containing age, sex, diabetes mellitus, primary kidney disease,
CVD, dialysis modality, current smoking, SGA, and albumin,
neither fetuin-A nor CRP levels predicted independently
death by infection (HR 0.86; CI 0.68–1.09 (P¼ 0.20) and
1.17; 0.88–1.60 (P¼ 0.28), respectively). Finally, because of
a possible different role of fetuin-A in diabetics and non-
diabetics,20 we evaluated the possibility of interaction between
the presence of diabetes and fetuin-A levels on mortality.
However, no such interaction was observed (P40.4).
Finally, we found significantly higher fetuin-A concentra-
tions in PD patients compared with HD patients. This is in
line with the results of our previous study in a smaller
number of prevalent dialysis patients.18 However, Stenvinkel
et al.16 did not find a difference in fetuin-A levels in HD and
PD patients after 12 months of renal replacement therapy.
Because of its molecular weight of about 60 kDa, fetuin-A will
not be lost to a significant degree during HD treatment,19
whereas it could potentially be lost in peritoneal drain
effluents in a similar way as albumin. On the other hand, in
our population, HD patients had higher CRP levels and this
could result in a pronounced downregulation of fetuin-A.
Also, PD patients were younger, had lesser CVD, and a
greater residual renal function. However, adjustment for all
these confounders did not sufficiently explain the consis-
tently observed differences in fetuin-A levels between HD and
PD patients. It is noteworthy, that despite these differences in
fetuin-A levels, associations between serum fetuin-A con-
centration and mortality did not differ significantly between
HD and PD patients in the presented cohort.
Our study had several potential limitations. The mortality
data rely on observations of the treating physicians. This
could induce some error in the definition of the exact cause
of mortality. Second, no imaging technique was applied
to evaluate the amount of arterial calcification in this
population. The relations between calcifications, mortality,
and fetuin-A levels therefore could not be explored in the
present study.
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Figure 3 | Bar chart showing the means (95% CI) of serum
fetuin-A concentration (g/l) in HD and PD patients after
adjustment for age, sex, diabetes, residual renal function,
hsCRP, CVD, Ca, P, and albumin.
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In summary, the present study shows that in a large
dialysis population, low fetuin-A levels are associated with
increased all-cause mortality, also after adjustment for
inflammation and malnutrition. This is both true for HD
and PD patients. Fetuin-A was found to be as strongly
associated with CV as with non-CV mortality. Therefore
although often exclusively regarded as a CV risk factor, a low
fetuin-A level is most likely a general risk factor for mortality
in dialysis patients.
MATERIALS AND METHODS
Patients
The Netherlands Cooperative Study on the Adequacy of Dialysis is a
large, prospective, multicenter cohort study in which patients with
end-stage renal disease are followed up from the initiation of dialysis
therapy until transplantation or death. All incident patients with
end-stage renal disease in 38 of 48 dialysis units in The Netherlands
were consecutively invited to participate in the study. Patients had
to be at least 18 years of age or older, with dialysis as their first
renal replacement therapy and had to give informed consent
before inclusion.
For the current analysis, we included incident HD and PD
patients who survived the first 3 months of dialysis and started on
long-term dialysis treatment between 1997 and October 2005.
Data collection procedures
Data on demography, primary kidney disease, and comorbidity were
collected at the time of entry in the study. Data on residual renal
function (rKt/V urea and urine production), biochemistry, and
dialysis characteristics (current modality, dKt/V urea) were collected
3 months after initiation of dialysis (baseline visit).
Primary kidney function and causes of death were classified
according to the codes of the European Renal Association-Dialysis
and Transplantation-Association (ERA-EDTA).21 The following
codes were classified as CV mortality: 0 (cause of death uncertain/
not determined), 11 (myocardial ischemia and infarction), 12
(hyperkalemia), 14 (other causes of cardiac failure), 15 (cardiac
arrest, cause unknown), 17 (hypokalemia), 18 (fluid overload), 22
(cerebrovascular accident), 26 (hemorrhage from ruptured vascular
aneurysm), and 29 (mesenteric infarction). All other codes were
regarded as deaths of non-CV origin, of which codes 31–39 were
classified as deaths due to infection.
Prevalent CVD was defined as the presence or history of ischemic
heart disease, peripheral vascular disease, heart failure, and/or
cerebrovascular disease. Comorbity was defined according to the
risk criteria of Khan et al.22 The Khan index is a combination of
age and comorbidity leading to three risk groups: low, medium,
and high.
Residual renal function was expressed as glomerular filtration
rate, calculated as the mean of creatinine and urea clearance
adjusted for body surface area (in milliliters/minute/1.73 m2).
Dialysis dose, expressed as Kt/V urea per week, was calculated as
dialysis urea clearance divided by urea distribution volume (V)
according to Watson et al.23 For HD patients, dialysis urea clearance
was calculated by using a second-generation Daugirdas formula,24
and for PD patients peritoneal Kt/V was calculated by using 24-h
dialysate collection.
All laboratory analyses were obtained from blood drawings
obtained 3 months after the initiation of dialysis treatment. In HD
patients, blood samples were taken just before the start of a HD
session after a short interval.
Plasma calcium, phosphorus, and albumin were measured using
standard laboratory techniques in the different centers. Calcium
concentration (mmol/l) was corrected for albumin concentration.
Both single point hsCRP and fetuin-A levels were measured
by nephelometry. Serum samples were stored at 801C before
analysis. Serum analysis for hsCRP were performed by means of
particle enhanced immunonephelometry using a standard ‘Cardio-
Phase hsCRP’ for ‘BNII’ (Dade Behring Holding GmbH, D-65835
Liederbach, Germany). CRPI or CRPII assay protocols were used
when appropriate. Interday precision controls revealed variation
coefficients below 6%.
The nephelometry method for fetuin-A employs the same high
specificity antibody as the enzyme-linked immunosorbent assay
method previously described15,25 with establishing reproducible
standard curves after testing for appropriate dilution. Thermo-
stability of fetuin-A was tested before nephelometry establishment.
Repetitive cycles of thawing and defrosting did not alter fetuin-A
levels compared with the reference storage method: The Netherlands
Cooperative Study on the Adequacy of Dialysis samples were stored
at 801C after sampling and serum preparation and transported at
dry ice. The nephelometric method for fetuin-A serum measure-
ment has been described previously.18,20 It was evaluated in a side-
by-side comparison with immunoblot analysis to exclude cross-
reactivity of the antibodies with other serum proteins and
proteolytic fragments of fetuin-A. For both methods, a polyclonal
rabbit anti-human fetuin-A antibody was used that does not
crossreact with fetuin-B. Final serum fetuin-A concentrations were
calculated by regression analysis of a serial dilution curve obtained
from standard serum. For comparison, a control solution of purified
serum fetuin-A powder (Boehringer Mannheim GmbH, Mannheim,
Dade-Behrging, Marburg, Germany) was prepared. Serum samples
were cleared by centrifugation (60 min at 15 000 g) and diluted
1:4 with 400 ml phosphate-buffered saline (N Diluent, Dade
Behring Holding, Liederbach, Germany). Nephelometric assays
were performed using an automatic nephelometer (BNII, Dade
Behring Holding, Liederbach, Germany). The assay linear measure-
ment range of human fetuin-A is 0.05 up to 3.5 g/l. The within run
precision obtained from a 20-fold measurement of identical samples
yielded a variation coefficients of 7.8%. The day-to-day precision
obtained from repetitive measurements of control serum was
determined as a variation coefficients of 8.5%.
The nutritional status was scored on the seven-point scale of the
SGA, which is a standardized method based on the clinical judgment
of the dialysis nurse.26
Patients with an SGA score of 5 or less were considered
malnourished.
Statistical analysis
Normally distributed variables were expressed as mean7s.d., and
non-normally distributed variables as median and range. Before
analysis non-normally distributed variables were log-transformed.
Patients were divided into tertiles according to fetuin-A concentra-
tions. Kaplan–Meier analysis was used to analyze crude CV and non-
CV mortality, according to fetuin-A concentration in tertiles. The
survival time of a patient was censored at the time of transplanta-
tion, withdrawal from the study or at the end of the study period
(1 October 2005).
To study fetuin-A concentration as an independent predictor of
mortality, we used four on clinical judgment predefined multivariate
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Cox proportional-hazards models. The first was a crude model,
which only contained serum fetuin-A as a continuous variable. The
second model contained age, sex, diabetes mellitus, primary kidney
disease, CVD, current smoking, and dialysis modality. Model three
was comparable with the second model, but parameters of nutri-
tional state such as SGA, albumin, and body mass index and log-
hsCRP were added. At last, model four was comparable with model
three with the additional adjustment for calcium and phosphorus.
We also studied the potential difference in HD and PD patients
of the associations between fetuin-A and mortality. Therefore, HRs
of the observed associations in HD and PD patients were compared.
In order to study the influence of inflammation on the
relationship between fetuin-A and mortality, the population was
divided by tertiles of hsCRP. We then compared the HRs of the
different CRP-fetuin combinations to study whether there was an
additive risk of a higher CRP on the association between fetuin-A
and mortality.
Standard descriptive statistics were used to examine differences
between HD and PD patients. Student’s t-tests were applied for
testing differences in continuous variables, and w2 tests were used to
compare distributions of dichotomous or categorical data Regres-
sion analysis was used to adjust for confounders. For all analyses,
Po0.05 was considered statistical significant. Statistical analyses
were performed using SPSS software, version 11.0 (SPSS Inc.,
Chicago, IL, USA)
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